We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Nuformix Plc | NFX | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.1025 | 08:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.1025 | 0.1025 | 0.1025 | 0.1025 | 0.1025 |
| Industry Sector |
|---|
| NONEQUITY INVESTMENT INSTRUMENTS |
| Top Posts |
|---|
Posted at 07/6/2025 18:03 by smackeraim Solvonis Therapeutics (LON:SVNS) is making headlines for all the right reasons - and their flagship addiction treatment, SVN-001, could soon become one of the most important breakthroughs in mental health.With the potential to transform the lives of millions battling alcohol use disorder, this revolutionary program is now in fully funded Phase III trials - the final step before potential market approval - and the data so far is nothing short of astonishing.SVN-001 isn't just another treatment - it's redefining what success looks like in addiction recovery.In Phase II trials, patients entered the program averaging just 2% sobriety - roughly seven sober days a year. After treatment, that number rocketed to 86% sobriety at six months post-treatment. That's not incremental improvement - that's life-changing transformation.Even more remarkable is how efficiently Solvonis is executing. The Phase III trial is being conducted in partnership with the UK Department of Health, supported by NHS addiction specialists, and being run at a cost of just £800,000 - a figure virtually unheard of in the biopharma world. With national health backing, this isn't just a trial - it's a potential blueprint for the UK's future in addiction care.Behind the science is a world-class leadership team. Professor David Nutt, one of the most recognised names in neuropsychopharmacol |
Posted at 30/5/2025 14:36 by the gerbilator DOnt know how you call yourselves investors. Bigging up SBTX from 88p to 7p over 3 years, and the tick chart is upsetting you all here |
Posted at 29/5/2025 09:13 by the gerbilator Conclusion:Add - these are the moments every investor truly waits for when adding - supposedly anyway |
Posted at 29/5/2025 08:58 by the gerbilator No point in being investors and holding red for 6 months for the pleasure of the title imo. Time is everything for everyone |
Posted at 22/5/2025 10:42 by washingmachine They are even making private investorsPay a premium to raise Absolute bandits |
Posted at 22/5/2025 09:03 by atlantic57 Aim has a rotten reputation and increasingly it looks like many investors are looking to avoid this market. |
Posted at 14/4/2025 09:09 by the gerbilator Wow. Delta flying through the roof and Volume stacking right behind it, progressively in periods of no book trades in the window. Even .6% as typeYou expecting any form of news or investor meet today or morning? |
Posted at 07/4/2025 14:17 by the gerbilator Pretty important to know even for investors at such a price, imo re the acc is a constant and aligned to M term |
Posted at 28/3/2025 12:15 by the gerbilator And of course, investors whom happily hold -90% lol |
Posted at 19/3/2025 08:18 by for fx sake Price dropping again. Where are the investors? |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
